Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of California, San Francisco National Institutes of Health (NIH) Gilead Sciences Abbott Merck |
---|---|
Information provided by: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT00444379 |
The primary purpose of this study is to determine whether a protease inhibitor-based antiretroviral regimen is more efficacious than a non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimen in promoting the regression of KS tumor burden in persons with AIDS-related KS in Africa.
Condition | Intervention | Phase |
---|---|---|
Kaposi's Sarcoma HIV Infections |
Drug: Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | A Randomized Comparison of Protease Inhibitor-Based Versus Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-Related Kaposi's Sarcoma in Sub-Saharan Africa |
Estimated Enrollment: | 224 |
Study Start Date: | April 2007 |
With the advent of the HIV epidemic, Kaposi's sarcoma (KS) is now the most common adult cancer in many parts of sub-Saharan Africa. In HIV-infected patients with KS in developed settings, the initiation of highly active anti-retroviral therapy (HAART) has been associated with regression of the tumor, in many but not all cases, even in the absence of conventional chemotherapy. However, it is not known which specific antiretroviral drugs or regimens are critical to convey HAART's anti-KS effect. In particular, it is not known whether the anti-KS effects of protease inhibitors (PI) in vitro and in animal models translate into improved clinical outcomes as compared to non-PI-based HAART regimens. To address this, we will determine whether a PI-based HAART regimen (lopinavir/ritonavir plus emtricitabine/tenofovir) is superior to a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART regimen (efavirenz plus emtricitabine/tenofovir) in promoting the regression of KS tumor burden in persons with AIDS-related KS in sub-Saharan Africa. We will enroll 224 patients with AIDS-related KS in Kampala, Uganda, randomly assign them to either a PI-based HAART or an NNRTI-based HAART regimen, and observe them for one year to determine the response in their KS to therapy.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Extensive degree of mucocutaneous KS, which would typically require chemotherapy or radiotherapy. This is defined by any of the following:
Suggestion of pulmonary or gastrointestinal visceral KS, as evidenced by any of the following:
Contact: Dr. Jeffrey N Martin, MD, MPH | 1 415 514 8010 | Martin@psg.ucsf.edu |
Contact: Dr. Edward K Mbidde, MBChB, MMed | 256 782630863 | mbiddek@UG.CDC.gov |
Uganda | |
Infectious Diseases Institute, Mulago Hospital | Recruiting |
Kampala, Uganda | |
Contact: Dr. Miriam O Laker, MBChB, MSc,DTM&H 256 772312326 drmiriaml@yahoo.co.uk | |
Contact: Dr. Victoria Walusansa, MBChB, MMed 256 782676455 walu203@yahoo.com | |
Principal Investigator: Dr. Jeffrey N Martin, MD, MPH | |
Principal Investigator: Dr. Edward K Mbidde, MBChB, MMed |
Principal Investigator: | Dr. Jeffrey N Martin, MD, MPH | University of California, San Francisco |
Principal Investigator: | Dr. Edward K Mbidde, MBChB, MMed | MRC/UVRI Uganda Research Unit on Aids |
Study ID Numbers: | NIH/NCI Grant #: R01 CA119903 |
Study First Received: | March 6, 2007 |
Last Updated: | January 13, 2009 |
ClinicalTrials.gov Identifier: | NCT00444379 History of Changes |
Health Authority: | United States: Institutional Review Board |
Kaposi's sarcoma KSHV AIDS HHV-8 treatment naive |
Sexually Transmitted Diseases, Viral Kaposi Sarcoma Reverse Transcriptase Inhibitors Neoplasms, Connective and Soft Tissue Soft Tissue Sarcomas Emtricitabine Lopinavir Anti-Retroviral Agents Tenofovir Retroviridae Infections Tenofovir disoproxil Efavirenz HIV Protease Inhibitors Anti-HIV Agents |
Sarcoma, Kaposi Acquired Immunodeficiency Syndrome Antiviral Agents Immunologic Deficiency Syndromes Herpesviridae Infections Protease Inhibitors Virus Diseases Malignant Mesenchymal Tumor HIV Infections Ritonavir Sexually Transmitted Diseases Sarcoma DNA Virus Infections |
Anti-Infective Agents Sexually Transmitted Diseases, Viral Slow Virus Diseases Molecular Mechanisms of Pharmacological Action Infection Reverse Transcriptase Inhibitors Neoplasms, Connective and Soft Tissue Anti-Retroviral Agents Emtricitabine Lopinavir Therapeutic Uses Neoplasms, Vascular Tissue Tenofovir Retroviridae Infections Nucleic Acid Synthesis Inhibitors |
Tenofovir disoproxil Efavirenz HIV Protease Inhibitors RNA Virus Infections Anti-HIV Agents Neoplasms by Histologic Type Immune System Diseases Sarcoma, Kaposi Acquired Immunodeficiency Syndrome Enzyme Inhibitors Antiviral Agents Pharmacologic Actions Immunologic Deficiency Syndromes Protease Inhibitors Herpesviridae Infections |